title: Supplement of a chitosan and ascorbic acid mixture for Crohn's disease: a pilot study.
abstract: OBJECTIVE
  Although the pathogenesis of Crohn's disease remains unclear, dietary fat is thought to exacerbate intestinal inflammation. Chitosan is a water-insoluble dietary fiber, and a chitosan and ascorbic acid mixture has been shown in rats to increase fecal fat excretion without affecting protein digestibility. However, it remains unclear whether a chitosan and ascorbic acid mixture is safe and effective for patients with Crohn's disease. We designed a pilot trial to investigate the tolerability and amount of fat excretion after the oral administration of a chitosan and ascorbic mixture for inactive Crohn's disease.
  
  
  METHODS
  Eleven outpatients were given seven tablets daily of a chitosan and ascorbic mixture (chitosan was given at 1.05 g/d) for 8 wk. Patients did not interrupt their respective therapies for Crohn's disease.
  
  
  RESULTS
  The bowel movements of most patients increased slightly during the study. Nutritional and inflammatory markers in patients did not differ before and after treatment. The chitosan and ascorbic acid mixture significantly increased the fat concentration in the feces during treatment.
  
  
  CONCLUSIONS
  These results indicated that oral administration of a chitosan and ascorbic acid mixture in patients with Crohn's disease is tolerable and increases fecal fat excretion without affecting disease activity.
authors.affiliation: Department of Internal Medicine, Division of Gastroenterology, Shiga University of Medical Science, and the Kirin Brewery Co., Ltd., Research Institute of Life Science, Shiga, Japan. tujikawa@belle.shiga-med.ac.jp
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Tsujikawa
authors.forename: Osamu
authors.initials: O
authors.lastname: Kanauchi
authors.forename: Akira
authors.initials: A
authors.lastname: Andoh
authors.forename: Takao
authors.initials: T
authors.lastname: Saotome
authors.forename: Masaya
authors.initials: M
authors.lastname: Sasaki
authors.forename: Yoshihide
authors.initials: Y
authors.lastname: Fujiyama
authors.forename: Tadao
authors.initials: T
authors.lastname: Bamba
mesh_terms: D000328:Adult; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D001205:Ascorbic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D001799:Blood Sedimentation / Q000187:drug effects; D002097:C-Reactive Protein / Q000187:drug effects; D002614:Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002686:Chitin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D048271:Chitosan; D002784:Cholesterol / Q000097:blood; D003424:Crohn Disease / Q000178:diet therapy / Q000378:metabolism*; D019587:Dietary Supplements / Q000706:statistics & numerical data*; D004064:Digestive System / Q000187:drug effects; D005223:Fats / Q000378:metabolism; D005243:Feces; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D013997:Time Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000975:Antioxidants; D002614:Chelating Agents; D005223:Fats; D014280:Triglycerides; D002686:Chitin; D002097:C-Reactive Protein; D048271:Chitosan; D002784:Cholesterol; D001205:Ascorbic Acid